SLC34A2 Recombinant Monoclonal Antibody

Code: CSB-RA021581MA2HU

Rate （N/A）
Review （0）

Size:

50μl100μl

US$210

Quantity:

Species Reactivity: Human

Application: ELISA

Send an Inquiry

Start an on-line Chat

Online ordering is currently available for U.S. customers only. For orders outside the U.S., please kindly submit an inquiry or start a chat with us.

Product Details
Related Products
Customer Reviews and Q&A
Target Background

Product Details

Uniprot NO.

O95436

Target Names

SLC34A2

Alternative Names

SLC34A2 antibody; Sodium-dependent phosphate transport protein 2B antibody; Sodium-phosphate transport protein 2B antibody; Na(+)-dependent phosphate cotransporter 2B antibody; NaPi3b antibody; Sodium/phosphate cotransporter 2B antibody; Na(+)/Pi cotransporter 2B antibody; NaPi-2b antibody; Solute carrier family 34 member 2 antibody

Species Reactivity

Human

Immunogen

Recombinant Human SLC34A2 protein

Conjugate

Non-conjugated

Clonality

Monoclonal

Isotype

hIgG1

Clone No.

7B6

Purification Method

Affinity-chromatography

Concentration

It differs from different batches. Please contact us to confirm it.

Buffer

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4

Form

Liquid
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.

Scope Application

ELISA Protocol

Recommended Dilution

Application	Recommended Dilution
ELISA	1:5000-1:50000

Storage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Lead Time

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Note: All of our proteins are default shipped with normal blue ice packs, if you request to ship with dry ice, please communicate with us in advance and extra fees will be charged.

Usage

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Datasheet & COA

Antibody FAQs

Images

The Binding Activity of Human SLC34A2 with Anti-SLC34A2 Recombinant Antibody
Activity: Measured by its binding ability in a functional ELISA. Immobilized Human SLC34A2(CSB-MP021581HU1) at 2 μg/mL can bind Anti-SLC34A2 recombinant antibody. The EC₅₀ is 32.86-37.66 ng/mL.
The purity of SLC34A2 was greater than 95% as determined by SEC-HPLC

Description

SLC34A2, also known as sodium-dependent phosphate transport protein 2B or NaPi-2b, plays a critical role in phosphate homeostasis by mediating the uptake of inorganic phosphate across epithelial cell membranes. This transporter is predominantly expressed in the lung and small intestine, where it facilitates essential phosphate absorption processes. Dysregulation of SLC34A2 has been implicated in pulmonary alveolar microlithiasis, a rare lung disorder, and emerging research has identified this transporter as a potential biomarker and therapeutic target in certain cancers, making it a protein of significant interest in both metabolic and oncological research.

This recombinant monoclonal antibody, clone 7B6, offers researchers the consistency and reliability that comes with sequence-defined production. Unlike traditional hybridoma-derived antibodies, recombinant technology ensures lot-to-lot reproducibility, allowing you to maintain experimental continuity across long-term studies without concerns about batch variation affecting your results.

Validation testing demonstrates robust binding activity against human SLC34A2, with functional ELISA data showing an EC50 range of 32.86 to 37.66 ng/mL when tested against immobilized recombinant human SLC34A2 protein at 2 μg/mL. The antibody itself exceeds 95% purity as confirmed by SEC-HPLC analysis, ensuring minimal background interference in your assays. For ELISA applications, dilutions ranging from 1:5000 to 1:50000 provide flexibility to optimize signal-to-noise ratios for your specific experimental conditions.

This antibody serves researchers investigating phosphate transport mechanisms, signal transduction pathways, and metabolic regulation, providing a dependable tool for advancing understanding of SLC34A2 biology in human systems.

Customer Reviews and Q&A

■ Customer Reviews

Submit a Review here

Target Background

Function(From Uniprot)

May be involved in actively transporting phosphate into cells via Na(+) cotransport. It may be the main phosphate transport protein in the intestinal brush border membrane. May have a role in the synthesis of surfactant in lungs' alveoli.

Gene References into Functions

The upstream breakpoint lies in the same region as the breakpoint of a fused gene SLC34A2-ROS1, which encodes a constitutive kinase in the lung cancer cell line HCC78 and nonsmall-cell lung cancer (NSCLC), suggesting that the deletion in this family is a hot spot for recombination, not only in cancer samples with somatic mutation, but also in PAM patients with germline genetic defects of SLC34A2. PMID:30262706
SLC34A2 plays a crucial promoting role in colorectal cancer development. PMID:29653487
Studied expression of solute carrier family 34 member 2 (SLC34A2/NaPi2b) in epithelial ovarian cancer using monoclonal antibody MX35 and immunohistochemistry. Different staining intensities were observed in different grades of epithelial ovarian cancer. PMID:28464843
Low SLC34A2 expression is associated with non-small cell lung cancer. PMID:26910912
SLC34A2 has an important role in promoting proliferation and tumorigenicity of BC. PMID:28151475
SLC34A2 was down-regulated in osteosarcoma patients.SLC34A2 interacted with PTEN, and decreased the phosphorylation of PI3K and AKT, which inactivated the PI3K/AKT signaling pathway. PMID:28777670
High expression of SLC34A2 was identified in about 2/3 patients and correlated with significantly better patient's overall survival. Epidermal growth factor receptor mutations were detected in about 53% of patients with no statistically significant difference to patient's overall survival. Anaplastic lymphoma kinase rearrangement was found in 8 out of 175 patients, harboring this abnormality leads to shorter overall survi PMID:28720066
we elucidated that miR-939 exerted its function mainly through inhibiting SLC34A2/Raf/MEK/ERK pathway, which is activated in GC. Multivariate analysis identified miR-939, SLC34A2, and their combination as independent indicators for poor prognosis and tumor recurrence in GC patients. PMID:28114937
a novel role of SLC34A2 inbreast cancer stem cells (BCSCs) state regulation and establishes a rationale for targeting the SLC34A2/PI3K/AKT/SOX2 signaling pathway for breast cancer therapy. PMID:28381172
Knockdown of SLC34A2 inhibits proliferation. PMID:28281971
Our work sheds new light on the nature of the state of lung cancer stem cell-like cells and the role of SLC34A2 in the tumorigenicity of these cells PMID:26846105
our data indicated that SLC34A2 could exert significantly suppressive effects on tumorigenesis and progression of NSCLC. SLC34A2 might provide new insights for further understanding the early pathogenesis of human non-small cell lung cancer PMID:26156586
SLC34A2 might be associated with the initiation and progression of lung adenocarcinoma PMID:25017204
Data indicate that humanized monoclonal antibody Rebmab200 and murine monoclonal antibody MX35 monoclonal antibodies had similar specificity for sodium phosphate transporter NaPi2b. PMID:23936189
investigation revealed that the c.910A > T mutation in the SCL34A2 gene was responsible for pulmonary alveolar microlithiasis (PAM) patients in China PMID:23164546
identified 2 cases of pulmonary alveolar microlithiasis(PAM) with new mutations of SLC34A2 gene; identified the NaPi-IIb in a aortic valve; hypothesize that mutations in SLC34A2 may play a role in development of aortic valve calcification and arteriosclerosis PMID:22336687
a comprehensive analysis indicates that SCL34A2 is the only gene of the several phosphate transporters genes whose expression differentiates normal from carcinoma samples, suggesting it might exert a major role in ovarian carcinomas. PMID:22553815
The performed study revealed that SLC34A2 gene exhibited the most distinct change in expression and may become a molecular marker of papillary thyroid cancer PMID:17091453
study provides the data on the pattern of NaPi2b expression and cellular localization in breast, lung and ovarian cancers PMID:21956469
Upregulation of SLC34A2 gene expression in well-differentiated tumors may reflect cell differentiation processes during ovarian cancerogenesis and could serve as potential marker for ovarian cancer diagnosis and prognosis. PMID:21716206
There was a significantly increased gene expression of SLC34A2 (normal tissues: 6.71+/-0.77; tumour tissues: 10.29+/-0.80) among breast cancer tissues compared with normal tissues. PMID:21036732
In human lung alveolar epithelial cells, the content of calcium and phosphate in cell supernatant decreased with increased amount of SLC34A2 mRNA. PMID:19134407
study describes mutations in SLC34A 2 gene in an inbred Turkish family with three siblings diagnosed with pulmonary alveolar microlithiasis(PAM); findings suggest that impaired activity of the SLC34A2 gene may be responsible for familial PAM PMID:20046000
A novel mutation in exon 8 of the SLC34A2 gene were associated with pulmonary alveolar microlithiasis in Chinese pedigree. PMID:20017296
The current study was performed to characterize the minimal promoter region and transcriptional factor(s) necessary to activate gene expression of NaPi-IIb in human intestinal cells. PMID:15458926
Study identified a pulmonary alveolar microlithiasis locus by homozygosity mapping to 4p15, then identified, by a candidate-gene approach, the gene responsible for the disease as SLC34A2, which is involved in phosphate homeostasis in several organs. PMID:16960801
Mutations in the SLC34A2 gene that abolish normal gene function cause pulmonary alveolar microlithiasis. PMID:17095743
The monoclonal antibodies were shown to recognize specifically transiently overexpressed and endogenous NaPi2b in commonly used immunoassays. PMID:18724815
SLC34A2 is associated with sodium-lithium countertransport activity and blood pressure PMID:19119262
The gene responsible for PAM, SLC34A2, has been identified. It encodes a type IIb sodium-dependent phosphate transporter, the function of which provides an insight into the pathogenesis of this disease. PMID:19617834

Hide All

Subcellular Location

Membrane; Multi-pass membrane protein.

Protein Families

SLC34A transporter family

Tissue Specificity

Highly expressed in lung. Also detected in pancreas, kidney, small intestine, ovary, testis, prostate and mammary gland. In lung, it is found in alveolar type II cells but not in bronchiolar epithelium.

Database Links

HGNC: 11020

UNIGENE: Hs.479372

KEGG: hsa:10568

STRING: 9606.ENSP00000371483

OMIM: 265100

Promotions